Skip to content

Brefeldin A-inhibited guanine nucleotide-exchange protein 1 (ARFGEF1)

Homo sapiens — UniProt Q9Y6D6

Gene: ARFGEF1Homo sapiensSwissProt reviewed

Data last refreshed: (UniProt release unknown)

Key facts

Brefeldin A-inhibited guanine nucleotide-exchange protein 1 (ARFGEF1) is a protein from Homo sapiens identified by UniProt accession Q9Y6D6, 1849 residues long. MolForge cross-references it against 0 known binders and 73 disease associations.

  • UniProt accession: Q9Y6D6; gene symbol ARFGEF1.
  • Organism: Homo sapiens.
  • Length: 1849 amino acids.
  • Top disease associations (Open Targets): developmental delay, impaired speech, and behavioral abnormalities, with or without seizures, Intellectual disability and Joubert syndrome.
  • 3D structure: AlphaFold model available.

Target properties

Protein nameBrefeldin A-inhibited guanine nucleotide-exchange protein 1
UniProt accessionQ9Y6D6
GeneARFGEF1
OrganismHomo sapiens
Length1849 residues
Molecular weight—
EC numbers—
Target class—
Subcellular location—
Keywords—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tierMEDIUM
Druggability score—
Pocket score—
Max clinical phase—

Disease associations (73)

Diseases linked to this target (Open Targets).

  • developmental delay, impaired speech, and behavioral abnormalities, with or without seizures · score 0.71
  • Intellectual disability · score 0.65
  • Joubert syndrome · score 0.55
  • Global developmental delay · score 0.53
  • Delayed speech and language development · score 0.53
  • Atypical behavior · score 0.52
  • genetic disorder · score 0.47
  • epilepsy · score 0.46
  • Seizure · score 0.45
  • Neurodevelopmental delay · score 0.38

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

StructureSourceMethodMean pLDDTResolution (Å)
AF-Q9Y6D6-F1alphafoldPREDICTED75.42—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9Y6D6.

Amino-acid sequence (1849 residues)

MYEGKKTKNM FLTRALEKIL ADKEVKKAHH SQLRKACEVA LEEIKAETEK QSPPHGEAKA GSSTLPPVKS KTNFIEADKY FLPFELACQS KCPRIVSTSL DCLQKLIAYG HLTGNAPDST TPGKKLIDRI IETICGCFQG PQTDEGVQLQ IIKALLTAVT SQHIEIHEGT VLQAVRTCYN IYLASKNLIN QTTAKATLTQ MLNVIFARME NQALQEAKQM EKERHRQHHH LLQSPVSHHE PESPQLRYLP PQTVDHISQE HEGDLDLHTN DVDKSLQDDT EPENGSDISS AENEQTEADQ ATAAETLSKN EVLYDGENHD CEEKPQDIVQ NIVEEMVNIV VGDMGEGTTI NASADGNIGT IEDGSDSENI QANGIPGTPI SVAYTPSLPD DRLSVSSNDT QESGNSSGPS PGAKFSHILQ KDAFLVFRSL CKLSMKPLSD GPPDPKSHEL RSKILSLQLL LSILQNAGPI FRTNEMFINA IKQYLCVALS KNGVSSVPEV FELSLSIFLT LLSNFKTHLK MQIEVFFKEI FLYILETSTS SFDHKWMVIQ TLTRICADAQ SVVDIYVNYD CDLNAANIFE RLVNDLSKIA QGRGSQELGM SNVQELSLRK KGLECLVSIL KCMVEWSKDQ YVNPNSQTTL GQEKPSEQEM SEIKHPETIN RYGSLNSLES TSSSGIGSYS TQMSGTDNPE QFEVLKQQKE IIEQGIDLFN KKPKRGIQYL QEQGMLGTTP EDIAQFLHQE ERLDSTQVGE FLGDNDKFNK EVMYAYVDQH DFSGKDFVSA LRMFLEGFRL PGEAQKIDRL MEKFAARYLE CNQGQTLFAS ADTAYVLAYS IIMLTTDLHS PQVKNKMTKE QYIKMNRGIN DSKDLPEEYL SAIYNEIAGK KISMKETKEL TIPTKSSKQN VASEKQRRLL YNLEMEQMAK TAKALMEAVS HVQAPFTSAT HLEHVRPMFK LAWTPFLAAF SVGLQDCDDT EVASLCLEGI RCAIRIACIF SIQLERDAYV QALARFTLLT VSSGITEMKQ KNIDTIKTLI TVAHTDGNYL GNSWHEILKC ISQLELAQLI GTGVKPRYIS GTVRGREGSL TGTKDQAPDE FVGLGLVGGN VDWKQIASIQ ESIGETSSQS VVVAVDRIFT GSTRLDGNAI VDFVRWLCAV SMDELLSTTH PRMFSLQKIV EISYYNMGRI RLQWSRIWEV IGDHFNKVGC NPNEDVAIFA VDSLRQLSMK FLEKGELANF RFQKDFLRPF EHIMKRNRSP TIRDMVVRCI AQMVNSQAAN IRSGWKNIFS VFHLAASDQD ESIVELAFQT TGHIVTLVFE KHFPATIDSF QDAVKCLSEF ACNAAFPDTS MEAIRLIRHC AKYVSDRPQA FKEYTSDDMN VAPEDRVWVR GWFPILFELS CIINRCKLDV RTRGLTVMFE IMKTYGHTYE KHWWQDLFRI VFRIFDNMKL PEQQTEKAEW MTTTCNHALY AICDVFTQYL EVLSDVLLDD IFAQLYWCVQ QDNEQLARSG TNCLENVVIL NGEKFTLEIW DKTCNCTLDI FKTTIPHALL TWRPNSGETA PPPPSPVSEK PLDTISQKSV DIHDSIQPRS VDNRPQAPLV SASAVNEEVS KIKSTAKFPE QKLFAALLIK CVVQLELIQT IDNIVFFPAT SKKEDAENLA AAQRDAVDFD VRVDTQDQGM YRFLTSQQLF KLLDCLLESH RFAKAFNSNN EQRTALWKAG FKGKSKPNLL KQETSSLACG LRILFRMYMD ESRVSAWEEV QQRLLNVCSE ALSYFLTLTS ESHREAWTNL LLLFLTKVLK ISDNRFKAHA SFYYPLLCEI MQFDLIPELR AVLRRFFLRI GVVFQISQPP EQELGINKQ

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with ARFGEF1?

The strongest Open Targets associations for ARFGEF1 are developmental delay, impaired speech, and behavioral abnormalities, with or without seizures, Intellectual disability, Joubert syndrome, Global developmental delay and Delayed speech and language development.

How long is the ARFGEF1 protein?

The Homo sapiens ARFGEF1 protein (UniProt Q9Y6D6) is 1849 amino acids long.

Browse: Targets: A · all protein targets A–Z · drugs A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Explore Brefeldin A-inhibited guanine nucleotide-exchange protein 1 with MolForge

Find binders, run structure-based screening, and map this target across diseases and approved drugs with our AI-powered platform.

Browse all targets

Quick facts

UniProtQ9Y6D6
GeneARFGEF1
OrganismHomo sapiens
Length1849
Binders0
Diseases73
View on UniProt